摘要
目的 观察较大剂量普伐他汀治疗急性心肌梗死患者 3d后金属蛋白酶 9(MMP 9)、可溶性白细胞分化抗原 40配体 (sCD40L)及C 反应蛋白 (CRP)的变化 ,以了解短期普伐他汀治疗对斑块稳定和免疫炎症抑制的影响。方法 35例急性心肌梗死患者随机分为常规治疗组 (无服用任何调脂药物 ,17例 )和普伐他汀组 ( 40mg/d ,18例 )治疗 ,测定治疗前后sCD40L、MMP 9、CRP和血脂水平的变化。结果 二组治疗前后血脂各组成分的变化差异均无显著性 ,而普伐他汀治疗组治疗后sCD40L、MMP 9及CRP水平分别降低 38%、48%、33%,与治疗前比较有统计学差异 (P <0 0 5 )。在普伐他汀治疗组 ,sCD40L、MMP 9的降低与TC(r =0 0 9,P =0 5 7;r =0 15 ,P =0 38)、LDL C(r =0 0 8,P =0 87;r= 0 0 3 ,P =0 83)的下降百分数之间无相关关系。结论 在急性心肌梗死的早期予以 3d的普伐他汀治疗 ,可明显减低血浆炎症因子的水平、可能有利于动脉粥样硬化斑块的稳定。
Objective To observe the influence of pravastatin on plasma sCD40L, MMP-9 and CRP level in patients of acute myocardial infarction within 3 days. Methods Thirty-five patients of acute myocardial infarction were randomized to either the pravastatin group (40mg/d of pravastatin for 3 days; n=18, 14men) or to the control group (no lipid-lowering drugs; n=17, 14 men). Plasma level of sCD40L,MMP-9 and CRP before and after treatment were detected. Results Levels of plasma lipid were not changed before and after treatment in both groups. Plasma levels of sCD40L, MMP-9 and CRP were significantly decreased 38%,48%,33% by pravastatin, respectively and there were no relations between the decrease percent of TC and LDL and that of sCD40L and MMP-9. Conclusion Pravastatin decreased plasma level of inflammatory factors in the patients of acute myocardial infarction within the first 3 days, so it may benefit to atherosclerotic plaque stabilization.
出处
《中华心血管病杂志》
CAS
CSCD
北大核心
2003年第3期165-168,共4页
Chinese Journal of Cardiology
